Sino-Biocan together with representatives from Chulalongkorn University of Thailand exemplifies their resolute determination in expanding into international markets

On April 25, 2024, Ms. Wei Dongbing, Chairwoman of Sino-Biocan Biotech Ltd., Professor Nattiya Hirankarn, Vice Dean of the Faculty of Medicine of Chulalongkorn University, Thailand, and Dr. Supannikar Tawinwung, Deputy Director of the Cell Immunology Research Laboratory, together visited the Institute of Hematology and Blood Diseases Hospital of the Chinese Academy of Medical Sciences (IHCAMS) in collaboration with Juventas Cell Therapy Ltd., a subsidiary of He Yuan Bio-technology (Tianjin) Co., Ltd. They engaged in a cordial exchange and delved into the possibilities of future close collaborations.

Chulalongkorn University is revered as the most prestigious university in Thailand as the oldest academy in this country. With 19 colleges, 2 graduate schools, 1 branch campus, 11 research institutes, 2 educational centers, and 3 affiliated schools, Chulalongkorn University is considered a pioneer in Thai higher education and a hub for academic research and excellent professional pursuits. It garners close attention from peers to the public, often influencing the country's higher education and research developments.

As a leading enterprise, Sino-Biocan actively responds to the national "Go Global" policy, continuously expanding its presence in international markets. This exchange and dialogue with Chulalongkorn University injects fresh vitality into Sino-Biocan's strategic deployment in global markets, laying a solid foundation for future international collaborations in the field of cell therapy.

During the visit, the delegation from Sino-Biocan engaged with representatives from the Institute of Hematology and Blood Diseases Hospital in discussions regarding the latest research advancements in the field of hematology and explored potential directions for future collaborations. Simultaneously, the delegation interacted with the executive team from Juventas Cell Therapy Ltd. on bio-pharmaceutical technology innovation and market expansion, delving into possibilities for future cooperation.

Sino-Biocan has been dedicated to propelling China's achievements in biopharmaceutical research onto the international stage. Through collaborations with top international research institutions and enterprises, the company aims to advance medical science collectively and make greater contributions to human health. This visit marks a further deepening of the longstanding friendly cooperation between Sino-Biocan and Chulalongkorn University, laying a robust foundation for future collaborations in the field of cell therapy.

Sino-Biocan will continue to uphold an open and inclusive attitude, maintaining close partnerships with top domestic and international research institutions and enterprises, united in their commitment to drive the progress of medical science and further advance human health endeavors. This exchange injects new impetus into Sino-Biocan's strategic positioning in both international and domestic markets, laying a solid groundwork for the company's future development in international cooperation and exchanges.